esophageal squamous cell carcinoma
Conditions
Interventions
1:IMRT is administered with chemotherapy from week 1 to week 8, PGTV-T 66-70Gy/33-35f, PGTV-N 60-66Gy/30-33f, PCTV-T 50-56Gy/25-28f, 50-56Gy/25-28f, docetaxel 60-75mg/m2 day 1 and cisplatin 25mg/m2 da
2:IMRT is administered with chemotherapy from week 1 to week 8, PGTV-T 66-70Gy/33-35f, PGTV-N 60-66Gy/30-33f, PCTV-T 50-56Gy/25-28f, 50-56Gy/25-28f. docetaxel 60-75mg/m2 day 1 and cisplatin 25mg/m2 da
Sponsors
Sichuan Cancer Hospital & Institute
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age18-80 years old, male or female; 2. Karnofsky score>=70; 3. Histologically confirmed diagnosis of esophageal squamous cell carcinoma; 4. Measurable Primary tumors; 5. Estimated life expectancy of at least 12 weeks; 6. Women in productive age should guarantee use contraceptives during study period; 7. WBC >=4.0*10^9/L, Absolute neutrophil count (ANC) >=2.0*10^9/L, Platelets >=100*10^9/L, Hemoglobin >=90g/L(without blood transfusion); 8. Liver function: AST (SGOT)/ALT (SGPT) <=2.5*upper limit of normal, Bilirubin <=1.5*upper limit of normal; 9. Renal function: Creatinine <=1.5*upper limit of normal; 10. This treatment is First treatment process; 11. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Have a distant metastasis; 2. The primary focal tumors or lymph node already had a surgical treatment (except for biopsy); 3. Already had a radiotherapy for primary focal or lymph node; 4. Patient who received the the epidermal growth factor targeted therapy; 5. The primary focal had received chemoradiotherapy or immunotherapy; 6.Patient who suffered from other malignant tumor (except for cured basal cell carcinoma or carcinoma in situ of cervix); 7. Subject who have taken other drug test in 1 month; 8. Pregnant woman or Lactating Women and Women in productive age who refuse take contraception in observation period; 9. Subject with a severe allergic history or idiosyncratic; 10. Subject with severe pulmonary and cardiopathic disease history; 11. Refuse or incapable to sign the informed consent form of participating this trial; 12. Drug abuse or alcohol addicted; 13. Subject with a Personality or psychiatric diseases, people with no legal capacity or people with limited capacity for civil conduct.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum VEGF;CT perfusion parameters: BV, BF, MTT, PS;Microvessel density (MVD) detection with endothel;Microvessel density (MVD) detection with endothel;Short term effective rate (RR);median survival time;overall survival;Quality of life(QoL); | — |
Countries
China
Contacts
Public ContactTao Li
Sichuan Cancer Hospital & Institute
Outcome results
None listed